Raloxifene as an Adjuvant Therapy for Patients With Schizophrenia: An Up-To-Date Systematic Review and Meta-Analysis.

Brain Behav · 2025 · PMC12277536 · PMID 40685802

Europe PMC DOI

hedged sentences

0.0600

closest p · 1.2× alpha

0.0600

boldest claim

The sentences

a trend toward significancep = 0.06so close (0.05 < p ≤ 0.1)

For negative symptoms, the improvement showed a trend toward significance with an MD of −1.35 (95% CI: −2.74 to 0.04; I 2 = 71%; p = 0.06; τ 2 = 3.27) (Figure 3 ). 3.4 Subgroup Analysis We conducted a subgroup analysis of different doses of raloxifene, duration, and menopausal status in women.

also in 1,131 other papers

showed a trendp = 0.06so close (0.05 < p ≤ 0.1)

For negative symptoms, the improvement showed a trend toward significance with an MD of −1.35 (95% CI: −2.74 to 0.04; I 2 = 71%; p = 0.06; τ 2 = 3.27) (Figure 3 ). 3.4 Subgroup Analysis We conducted a subgroup analysis of different doses of raloxifene, duration, and menopausal status in women.

also in 16,965 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.